首页> 外文OA文献 >Viral vector-based prime-boost immunization regimens: a possible involvement of T-cell competition
【2h】

Viral vector-based prime-boost immunization regimens: a possible involvement of T-cell competition

机译:基于病毒载体的初免-加强免疫方案:可能涉及T细胞竞争

摘要

Vaccination with recombinant viral vectors may be impeded by preexisting vector-specific immunity or by vector-specific immunity induced during the priming immunization. It is assumed that virus-neutralizing antibodies represent the principal effector mechanism of vector-specific immunity, while killing of infected cells by vector-specific cytotoxic T lymphocytes (CTLs) has also been suggested. Using recombinant Semliki Forest virus (rSFV) expressing E6E7 antigen from human papillomavirus, we demonstrate that secondary immune responses against E6E7 are neither affected by vector-specific antibodies nor by CTL-mediated killing of infected cells. Instead, the presence of the antigen during the prime immunization appeared to be the main determinant for the boosting efficacy. After priming with rSFVeE6,7, a homologous booster stimulated the primed E6E7-specific CTL response and induced long-lasting memory. Passively transferred SFV-neutralizing antibodies did not inhibit E6E7-specific CTL responses, although transgene expression was strongly reduced under these conditions. Conversely, in mice primed with irrelevant rSFV, induction of E6E7-specific CTLs was inhibited presumably due to vector-specific responses induced by the priming immunization. When during the priming with irrelevant rSFV, E7-protein was co-administered, the inhibitory effect of vector-specific immunity was abolished. These results suggest that, apart from vector-specific antibodies or killing of infected cells, T-cell competition may be involved in determining the efficacy of viral vector-based prime-boost immunization regimens.
机译:预先存在的载体特异性免疫或初免免疫过程中诱导的载体特异性免疫可能会阻碍重组病毒载体的疫苗接种。假定病毒中和抗体代表了载体特异性免疫的主要效应器机制,同时也有人提出载体特异性细胞毒性T淋巴细胞(CTL)杀死感染的细胞。使用从人乳头瘤病毒表达E6E7抗原的重组Semliki森林病毒(rSFV),我们证明针对E6E7的次级免疫应答既不受载体特异性抗体的影响,也不受CTL介导的感染细胞杀伤的影响。相反,在初次免疫过程中抗原的存在似乎是增强效力的主要决定因素。用rSFVeE6,7引发后,同源增强剂刺激了引发的E6E7特异性CTL反应并诱导了持久的记忆。被动转移的SFV中和抗体不会抑制E6E7特异性CTL反应,尽管在这些条件下转基因表达会大大降低。相反,在不相关rSFV引发的小鼠中,E6E7特异性CTL的诱导被认为是由于引发免疫所诱导的载体特异性应答而被抑制的。当在与无关的rSFV一起引发期间,共同施用E7蛋白时,消除了载体特异性免疫的抑制作用。这些结果表明,除载体特异性抗体或杀死感染的细胞外,T细胞竞争可能参与确定基于病毒载体的初免-加强免疫方案的效力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号